DTaP-Hib vaccine

From Wikipedia, the free encyclopedia
DTaP-Hib vaccine
Combination of
DTaP vaccineVaccine
Hib vaccineVaccine
Clinical data
Trade namesTriHIBit, ActHIB with Tripedia
Routes of
administration
Intramuscular injection
ATC code
Identifiers
CAS Number

DTaP-Hib vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed with Haemophilus B conjugate vaccine, sometimes abbreviated to DTaP-Hib.[1] It protects against the infectious diseases diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.[citation needed]

A branded formulation was marketed in the US as TriHIBit by Sanofi Pasteur, and administered by using the Sanofi DTaP vaccine Tripedia to reconstitute the Sanofi Hib vaccine ActHIB.[2][3][4] TriHIBit and Tripedia were discontinued in 2011.[5] The current Sanofi DTaP formulation is Daptacel.

References[edit]

  1. ^ "Trihibit (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) Disease Interactions". Drugs.com. Retrieved 15 July 2018.
  2. ^ "Notice to Readers FDA Approval of a Haemophilus b Conjugate Vaccine Combined by Reconstitution with an Acellular Pertussis Vaccine". Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention. 15 November 1996. pp. 993–995. Retrieved 15 July 2018.
  3. ^ "Tripedia package insert" (PDF). US Food and Drug Administration. Archived from the original (PDF) on 12 January 2017. Retrieved 15 July 2018.
  4. ^ "ActHIB package insert" (PDF). US Food and Drug Administration. Retrieved 15 July 2018.
  5. ^ "Selected Discontinued U.S. Vaccines" (PDF). Centers for Disease Control and Prevention. Retrieved 15 July 2018.